Literature DB >> 19029913

Human embryonic stem cells reveal recurrent genomic instability at 20q11.21.

Nathalie Lefort1, Maxime Feyeux, Cécile Bas, Olivier Féraud, Annelise Bennaceur-Griscelli, Gerard Tachdjian, Marc Peschanski, Anselme L Perrier.   

Abstract

By analyzing five human embryonic stem (hES) cell lines over long-term culture, we identified a recurrent genomic instability in the human genome. An amplification of 2.5-4.6 Mb at 20q11.21, encompassing approximately 23 genes in common, was detected in four cell lines of different origins. This amplification, which has been associated with oncogenic transformation, may provide a selective advantage to hES cells in culture.

Entities:  

Mesh：

Year:  2008        PMID： 19029913     DOI： 10.1038/nbt.1509

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  87 in total

Review 1.  Delineating nuclear reprogramming.

Authors:  Jolene Ooi; Pentao Liu
Journal:  Protein Cell       Date:  2012-03-31       Impact factor: 14.870

2.  Quality of Cell Products: Authenticity, Identity, Genomic Stability and Status of Differentiation.

Authors:  Kurt E J Dittmar; Meike Simann; Nadia Zghoul; Oliver Schön; Wilhelm Meyring; Horst Hannig; Lars Macke; Wilhelm G Dirks; Konstantin Miller; Henk S P Garritsen; Werner Lindenmaier
Journal:  Transfus Med Hemother       Date:  2010-03-08       Impact factor: 3.747

3.  High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity.

Authors:  Elisa Närvä; Reija Autio; Nelly Rahkonen; Lingjia Kong; Neil Harrison; Danny Kitsberg; Lodovica Borghese; Joseph Itskovitz-Eldor; Omid Rasool; Petr Dvorak; Outi Hovatta; Timo Otonkoski; Timo Tuuri; Wei Cui; Oliver Brüstle; Duncan Baker; Edna Maltby; Harry D Moore; Nissim Benvenisty; Peter W Andrews; Olli Yli-Harja; Riitta Lahesmaa
Journal:  Nat Biotechnol       Date:  2010-03-28       Impact factor: 54.908

4.  Differences between karyotypically normal and abnormal human embryonic stem cells.

Authors:  S Yang; G Lin; Y-Q Tan; L-Y Deng; D Yuan; G-X Lu
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

Review 5.  Human stem cells and drug screening: opportunities and challenges.

Authors:  Allison D Ebert; Clive N Svendsen
Journal:  Nat Rev Drug Discov       Date:  2010-03-26       Impact factor: 84.694

6.  Developing safe therapies from human pluripotent stem cells.

Authors:  Melissa K Carpenter; Joyce Frey-Vasconcells; Mahendra S Rao
Journal:  Nat Biotechnol       Date:  2009-07       Impact factor: 54.908

Review 7.  Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.

Authors:  Chad Tang; Micha Drukker
Journal:  Semin Immunopathol       Date:  2011-04-11       Impact factor: 9.623

8.  Recurrent copy number variations in human induced pluripotent stem cells.

Authors:  Kristen Martins-Taylor; Benjamin S Nisler; Seth M Taapken; Tiwanna Compton; Leann Crandall; Karen Dyer Montgomery; Marc Lalande; Ren-He Xu
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

Review 9.  The tumorigenicity of human embryonic and induced pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

10.  Functional in vivo and in vitro effects of 20q11.21 genetic aberrations on hPSC differentiation.

Authors:  Hye-Yeong Jo; Youngsun Lee; Hongryul Ahn; Hyeong-Jun Han; Ara Kwon; Bo-Young Kim; Hye-Yeong Ha; Sang Cheol Kim; Jung-Hyun Kim; Yong-Ou Kim; Sun Kim; Soo Kyung Koo; Mi-Hyun Park
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.